Placeholder Banner

BIO Comments on USTR Objectives for U.S. – Japan Trade Agreement

December 12, 2018

BIO welcomes progress made in recent U.S. bilateral trade agreements, in particular with Australia and Korea, to require transparency and accountability of foreign government pricing and reimbursement of biopharmaceuticals, to ensure market access and reward for innovation. BIO believes that to ensure that U.S. trading partners are allowing fair, non-discriminatory access to new medicines, and shouldering a fair share of the costs of innovation, that any modern trade agreement, including a U.S-Japan agreement should build on these provisions.  

Download Full Comments Below
BIO Negotiations Objectives - US-Japan Trade Final 112618
Discover More
On November 9, BIO submitted comments on the FDA Draft Guidance, Drug-Drug Interaction Assessment for Therapeutic Proteins. In the comments, BIO thanks the FDA for the opportunity to submit comments but requests that the Guidance include a…
On August 6, BIO submitted comments on the NMPA Draft Technical Guideline on Clinical Trials of Cellular Immunotherapy Products. In the comments, BIO thanks NMPA for the opportunity to submit comments but argues for a more robust commenting period…
October 30, 2020 Re: Docket No. FDA–2020-D-1564: FDA Draft Guidance, Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Dear Sir/Madam: The Biotechnology…